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OBJECTIVE—We performed a comprehensive genetic associa-
tion study of common variation spanning the IGF2BP2 locus in
order to replicate the association of the “conﬁrmed” type 2
diabetes susceptibility variants rs4402960 and rs1470579 in the
French Caucasian population and to further characterize the
susceptibility variants at this novel locus.
RESEARCH DESIGN AND METHODS—We genotyped a total
of 21 tagging single nucleotide polymorphisms spanning the
IGF2BP2 locus in our type 2 diabetes case-control cohort
comprising 3,093 French Caucasian subjects.
RESULTS—IGF2BP2 variants rs4402960 and rs1470579 were
not associated with type 2 diabetes in the present study (P 
0.632 and P  0.896, respectively). Meta-analysis of genotype
data from over 34,000 subjects demonstrated that our inability to
replicate rs4402960/rs1470579 was consistent with the ﬁndings
from several previous genome-wide association study (GWAS)
datasets that were underpowered to detect this modest associa-
tion signal (odds ratio [OR] 1.14). We obtained novel evidence
that rs9826022, a borderline rare variant (5% minor allele fre-
quency) in the 3 downstream region, was associated with type 2
diabetes (P  0.0002; OR 1.53 [95% CI 1.22–1.91]). This result was
corroborated by the meta-analysis of 10,542 genotypes from the
current study and GWAS datasets using both ﬁxed (P  9.47 
10
6; 1.30 [1.16–1.46]) and random effects (P  0.001; 1.30
[1.11–1.52)] calculations.
CONCLUSIONS—We were unable to replicate the conﬁrmed
rs4402960/rs1470579 susceptibility variants but found novel evi-
dence for a rare variant in the 3 downstream region of IGF2BP2.
Further genetic and functional studies are required to identify the
etiological IGF2BP2 variants. Diabetes 57:1992–1996, 2008
T
he insulin-like growth factor 2 mRNA binding
protein 2 (IGF2BP2) gene on chromosome 3q27
is a paralog of IGF2BP1, a known regulator of
IGF2 gene expression. Genome-wide association
studies (GWASs) carried out by the Finland-U.S. Investi-
gation of NIDDM Genetics (FUSION) (1), the Wellcome
Trust Case Control Consortium (WTCCC) (2), and the
Diabetes Genetics Initiative (DGI) (3) groups each found
modest evidence that single nucleotide polymorphisms
(SNPs) in the IGF2BP2 region are associated with type 2
diabetes. The subsequent meta-analysis of primary and
replication datasets from these GWASs corroborated these
ﬁndings and identiﬁed two strongly correlated IGF2BP2
variants, rs1470579 and rs4402960, as “conﬁrmed” type 2
diabetes susceptibility variants (1–3). By contrast, the
French/Canadian GWAS (4) typed 10 SNPs across the
IGF2BP2 locus, including rs1470579, in 1,363 subjects, but
found no nominal (P  0.05) association signals at
IGF2BP2. In an attempt to replicate the IGF2BP2 associ-
ation ﬁndings in the French Caucasian population in a
larger study and to further characterize the susceptibility
variants at this novel locus, we performed an association
study of HapMap Phase II tag SNPs spanning the IGF2BP2
locus in 3,093 French Caucasian subjects.
RESEARCH DESIGN AND METHODS
All subjects were of French Caucasian ancestry. Individuals identiﬁed by
Sladek et al. (4) as lying outside the HapMap CEU ancestry cluster were
excluded from the study. Type 2 diabetic case subjects were known diabetic
patients. Normoglycemic control subjects were selected to have a fasting
blood glucose concentration 7.0 mmol/l (5). Case subjects were composed
of 1) 372 probands from diabetic families (6), recruited in Lille; and 2) 1,083
patients with a family history of type 2 diabetes, recruited at the Corbeil-
Essonne Hospital. Control subjects were composed of 1) 353 normoglycemic
parents from type 2 diabetic families; 2) 543 subjects from the SUVIMAX
(Supplementation en Vitamines et Mine ´raux Antioxidant) prospective popu-
lation-based cohort study (7); and 3) 742 subjects selected from the DESIR
(Data from an Epidemiologic Study on the Insulin Resistance Syndrome)
cohort, a large prospective study of insulin resistance in French subjects (8).
Informed consent was obtained from all subjects, and the study was approved
by local ethics committees.
Statistical power. The case-control cohort comprised 1,455 type 2 diabetic
subjects (age 60  12 years, BMI 29.0  6.0 kg/m
2, sex [male:female] 56:44%)
and 1,638 normoglycemic subjects (aged 54  13 years, BMI 24.1  3.3 kg/m
2,
sex 43:57%). At 0.05, this sample size provided 76% power (9) to detect the
type 2 diabetes susceptibility variants rs1470579 and rs4402960, assuming an
allele frequency of 0.30, a disease prevalence of 0.1, a heterozygote relative
risk of 1.14 (1–3), a multiplicative model, and a 100% genotype call rate.
IGF2BP2 tag SNP selection. The genomic target region for tag SNP
selection was extended 10 kb upstream and downstream of the NCBI36
IGF2BP2 locus (chr. 3:186,844,221.0.187,025,521). A total of 19 HapMap Phase
II multimarker tagging SNPs (HapMap Data Release 21a/Jan07) with r
2 and
minor allele frequency thresholds of 0.8 and 0.05, respectively, were identiﬁed
for genotyping. In addition, the two GWAS-identiﬁed susceptibility variants
rs4402960 and rs1470579 (1–3) were added to the genotyped SNP set, making
a total of 21 genotyped SNPs.
SNP genotyping. Genotyping was performed with the Sequenom MassAR-
RAY iPLEX system (10). SNP genotype frequencies were tested for accor-
dance with Hardy-Weinberg equilibrium using 
2 analysis. Regarding quality
control, all 21 genotyped SNPs exhibited a call rate 	90% and a Hardy-
Weinberg P 	 0.05, with well-deﬁned genotype clusters. There was no
evidence (at 0.01) of differential call rates across case and control
subjects for any SNP (supplementary Table 2 [available in an online appendix
at http://dx.doi.org/10.2337/db07-1789]).
From the
1Section of Genomic Medicine, Imperial College London, Hammer-
smith Campus, London, U.K.; the
2Endocrinology-Diabetology Unit, Corbeil
Hospital, Corbeil, France; the
3Endocrinology-Diabetology Unit, Bichat
Hospital, Paris, France;
4INSERM U695, Paris, France; the
5Institut Re ´gional
Pour la Sante ´, Tours, France;
6INSERM U557/U1125 Inra/Cnam/University
Paris, Bobigny, France;
7INSERM U780-IFR69, Villejuif, France;
8Paris
Univ-Sud, Orsay, France; and
9CNRS 8090, Institut de Biologie de Lille,
Institut Pasteur, Lille, France.
Corresponding author: Fernando Gibson, fernando.gibson@imperial.ac.uk.
Received 17 December 2007 and accepted 17 April 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 22 April
2008. DOI: 10.2337/db07-1789.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
BRIEF REPORT
1992 DIABETES, VOL. 57, JULY 2008Statistical analyses. To test for association of IGF2BP2 SNPs with type 2
diabetes, 
2 analysis of allele and genotype counts was performed. Pairwise
SNP linkage disequilibrium (LD) values were calculated from the genotype
data of the control cohort with Haploview (11). Quantitative metabolic
phenotypes, BMI, waist-to-hip ratio, fasting serum levels of triacylglycerol,
total and HDL cholesterol, glucose, insulin, apolipoprotein A-I (ApoA1), and
apolipoprotein B (ApoB), measured in 1,539 normoglycemic subjects from the
control cohort, were log transformed and adjusted for age, sex, and BMI, as
appropriate. SNPs were tested for association with adjusted quantitative traits
using SPSS 14.0 with the ANOVA test under a codominant model. Quantitative
trait association P values are presented uncorrected for multiple testing.
Combined analysis of association datasets was carried out with the Mantel-
Haenszel (ﬁxed effects) meta-analysis method. Interstudy heterogeneity was
assessed with Cochran’s Q statistic and the I
2 metric (12,13). All calculations
were performed using R (version 2.5.1) statistical software and the Meta
(version 0.8–2) package (14). Association analysis of SNPs captured by
multimarker tags was carried out with the PLINK software package (15).
Haplotype association was performed with the WHAP (version 2.09) software
package (16).
RESULTS AND DISCUSSION
A total of 21 HapMap Phase II multimarker tag SNPs (r
2 
0.8; minor allele frequency 0.05) spanning the IGF2BP2
locus, including the susceptibility variants rs4402960 and
rs1470579, were tested for association with type 2 diabetes
in 3,093 French subjects. The allele and genotype counts
for all SNPs are presented in online supplementary Tables
1 and 2, respectively. Figure 1 shows that SNPs rs4402960
and rs1470579 exhibited very strong LD (r
2  0.95) in
agreement with the GWAS (1–3) and HapMap data (17).
However, the allele frequencies of SNPs rs4402960 and
rs1470579 were not signiﬁcantly different in the case and
control groups (rs4402960, P  0.632; rs1470579, P 
0.896), indicating that these variants were not associated
with type 2 diabetes in the present study (Table 1). None
of the three SNPs captured by multimarker tags
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FIG. 1. Pattern of linkage disequilibrium between IGF2BP2
SNPs. Plot of pairwise SNP r
2 values calculated from control
genotype data. The plot was drawn to scale using LocusView (T.
Petryshen, A. Kirby, M. Ainscow, unpublished software).
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DIABETES, VOL. 57, JULY 2008 1993(rs4575929, P  0.159; rs4686692, P  0.566; and
rs16860216, P  0.972;) were associated with type 2
diabetes (online supplementary Table 3).
Our inability to replicate the conﬁrmed rs4402960/
rs1470579 association result can be attributed to a lack of
power to detect this modest signal. An examination of the
published association evidence for these variants (Fig. 2A
and B and online supplementary Tables 4 and 5) illustrates
this point and demonstrates that our results are not
inconsistent with those of previous studies. Of the nine
published rs4402960 datasets, the three statistically well-
powered studies (those with 90% power) all obtained an
association for this variant, while the six underpowered
studies showed either no association or a weak associa-
tion with type 2 diabetes. Overall, the combined data
shows a 3% difference in allele frequency between the case
and control groups in over 34,000 subjects, which equates
to very strong evidence of association (P  1.9  10
14;
OR 1.13 [95% CI 1.10–1.17]). Similarly for the rs1470579
variant, the underpowered datasets were either nonsignif-
icant or weakly associated with type 2 diabetes. The
combined data shows a 2% allele frequency difference in
over 22,000 case-control subjects and a clearly signiﬁcant
association with type 2 diabetes (P  2.6  10
9; 1.13
[1.09–1.18]). All of this serves as a reminder that the
meta-analysis of individually underpowered studies has an
invaluable role to play in the identiﬁcation and conﬁrma-
tion of susceptibility variants of small effect.
The between-study heterogeneity metric I
2 (12,13) was
calculated for these two variants (Fig. 2D). Heterogeneity
was moderate for rs4402960 (I
2  21%) in agreement with
a recent study (18). For rs1470579, the meta-analyzed
signal is clearly driven by the DGI Replication set “S”
result (P  3.73  10
8). In accordance with this standout
result and the smaller number of studies available for this
SNP, heterogeneity was higher (I
2  58%); the random
effects OR gave a mere P  0.001 compared with the
Mantel-Haenszel P  2.56  10
9; and Cochran’s Q statis-
tic was also statistically signiﬁcant (P  0.037).
We obtained novel evidence that rs9826022 in the 3
downstream region (P  0.0002; OR 1.53 [95% CI 1.22–
1.91]) was associated with type 2 diabetes (Table 1). This
result survived Bonferroni correction for the number of
SNPs tested (adjusted P  0.003), and we sought conﬁr-
mation in the publicly available GWAS data. The WTCCC
(http://www.wtccc.org.uk/) and DGI (http://www.broad
.mit.edu/diabetes/) GWAS did not directly type the
rs9826022 variant but instead typed rs9878208, an
rs9826022 proxy (HapMap r
2  1). Meta-analysis of this
data (Fig. 2C and online supplementary Table 6) provided
support for the association, although the random effects
evidence (P  0.001) was weaker than that produced by
the Mantel-Haenszel analysis (P  9.47  10
6). The
heterogeneity between these three studies was moderate
(I
2  44%). The disparity between the ﬁxed and random
effects may indicate that rs9826022 is not the “causative”
variant but merely in partial LD with the true susceptibility
variant; or it may simply reﬂect the “winner’s curse” result
of the present study and the inherently larger variance of
the genetic effect of rare variants in moderately sized
studies. The rs9826022 result will clearly require conﬁrma-
tion in further large, independent studies before a deﬁni-
tive assessment of the contribution of this rare variant to
type 2 diabetes susceptibility can be made.
The only other nominal association signal, rs9864104
(P  0.012; OR 1.19 [95% CI 1.04–1.37]), was modest and
disappeared upon multiple test correction. Since
rs9826022 and rs9864104 were in low-moderate LD (r
2 
0.26), we carried out haplotype analysis of these variants.
Two SNP haplotypes containing the rare allele of
rs9826022 showed a virtually identical frequency and P
value as the single-point rs9864104 analysis (online sup-
plementary Table 7), indicating that the haplotype analysis
did not add anything to the single-point analysis and that
the weak rs9864104 signal was caused by this variant being
in partial LD with rs9826022. There were no signiﬁcant
differences in SNP allele frequencies between men and
women, and no association with type 2 diabetes was
uncovered by stratifying for sex (data not shown).
SNPs rs4402960, rs1470579, rs9826022, and rs9864104
were also tested for association with a number of meta-
bolic quantitative phenotypes (online supplementary Ta-
ble 8). SNPs rs4402960 and rs1470579 presented weak
associations with ApoA1 (P  0.019 and 0.028, respec-
tively). SNP rs9864104 was associated with ApoA1 (P 
0.008) and ApoB levels (P  0.002), although there was no
linear trend between the three genotype groups. The
association of IGF2BP2 variation with apolipoprotein
levels may be consistent with the role of the insulin-like
growth factor system in regulating lipid metabolism. How-
ever, in the absence of replication, we emphasize that
these quantitative trait associations are of nominal signif-
icance and require conﬁrmation in further large studies.
In conclusion, we have carried out a comprehensive
TABLE 1
Association of IGF2BP2 SNPs with type 2 diabetes: conﬁrmed susceptibility SNPs rs4402960 and rs1470579 and SNPs showing
nominal association (P  0.05) in French Caucasians
SNP
Chr. Position
(bp) NCBI36
Gene
region* Allele
Allele count
P OR (95% CI)
Type 2
diabetic case
subjects (%)
Normoglycemic
control
subjects (%)
rs9826022 186,839,954 3 downstream A 2,532 (93.0) 2,949 (95.3) 0.0002 1.53 (1.22–1.91)
(
4267 bp) G 190 (7.0) 145 (4.7)
rs9864104 186,840,225 3 downstream C 2,260 (81.7) 2,628 (84.2) 0.012 1.19 (1.04–1.37)
(
3996 bp) T 506 (18.3) 494 (15.8)
rs4402960 186,994,381 Intron 6 G 1,786 (67.5) 2,111 (68.1) 0.632 1.03 (0.92–1.15)
T 858 (32.5) 987 (31.9)
rs1470579 187,011,773 Intron 5 A 1,753 (67.3) 2,120 (67.4) 0.896 1.01 (0.90–1.13)
C 853 (32.7) 1,024 (32.6)
Data are n (%) unless otherwise indicated. *Relative to the NCBI36 coordinates of the IGF2BP2 genomic locus (chr.
3:186,844,221.0.187,025,521). 
2 P values are shown.
IGF2BP2 VARIANTS AND TYPE 2 DIABETES
1994 DIABETES, VOL. 57, JULY 2008association study of common variation spanning the
IGF2BP2 locus and type 2 diabetes in French Caucasians.
We were unable to replicate the conﬁrmed susceptibility
variants rs4402960 and rs1470579 but found novel evi-
dence for a rare variant in the 3 downstream region of
IGF2BP2. Further genetic and functional studies are re-
quired to identify the etiological variants at the IGF2BP2
locus and to determine the cellular and physiological
mechanisms by which they act to modulate type 2 diabetes
susceptibility.
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